Company research
Apimeds Pharmaceuticals US, Inc.
CIK 1894525Updated Nov 6, 2026
SecurityAPUS · NYSE_AMERICAN · equity
APUS price & chart
Loading TradingView…
AMEX:APUS on TradingView ↗About the company
We are a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects. Apitox is currently marketed and sold by Apimeds Inc. (“Apimeds Korea”) in the South Korea as “Apitoxin.” Apimeds US is not associated with the market, sale and revenues generated from Apitoxin in South Korea, and Apitoxin has not been approved by the U.S. Food and Drug Administration (the “FDA”) for any indication. Apimeds is currently developing Apitox as a potential osteoarthritis (“OA”) treatment for patients with knee pain who failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.
In the news
Here’s What Investors Are Watching, Including $20 Price Target Bombshell ↗
Recent filings
Other Events
Items 8.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Other Events
Items 8.01, 9.01
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 3.03, 5.03, 9.01
Entry into a Material Definitive Agreement · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 1.01, 5.02, 9.01
Show 5 more recent filings
Entry into a Material Definitive Agreement
Items 1.01, 9.01
10-Q filing
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
10-Q filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| AssetsUSD | 9,250,036Source | — | 127,623,697Source | 10,546,681Source | — | 141,219,157Source | 259,904Source | — | 164,183,736Source | 13,057Source | 422,076Source |
| Property, Plant and Equipment, NetUSD | 34,188Source | — | 51,929Source | 13,137Source | — | 56,592Source | — | — | 51,626Source | — | — |
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 6,986,617Source | — | 278,371Source | 8,735,323Source | — | 979,534Source | 250,432Source | — | 1,636,655Source | 3,455Source | 410,481Source |
| Assets, CurrentUSD | 9,086,108Source | — | 10,678,438Source | 10,349,549Source | — | 13,153,203Source | 259,904Source | — | 13,983,859Source | 13,057Source | 422,076Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,099,491Source | — | — | 1,614,226Source | — | 2,625,169Source | 9,562Source | — | 2,298,704Source | 9,602Source | 11,595Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | 156,162Source | — | — | 171,779Source | — | — | 187,395Source | — | — |
| LIABILITIES AND EQUITY | |||||||||||
| LiabilitiesUSD | 1,089,384Source | — | 21,175,156Source | 809,002Source | — | 14,703,698Source | 2,020,422Source | — | 10,835,909Source | 1,371,178Source | 390,207Source |
| Stockholders’ equity: | |||||||||||
| Preferred Stock, Value, IssuedUSD | — | — | 748Source | — | — | 74,770Source | — | — | 74,770Source | — | — |
| Common Stock, Value, IssuedUSD | 125,760Source | — | 1,509Source | 125,760Source | — | 125,760Source | 79,039Source | — | 125,760Source | 79,039Source | 79,039Source |
| Additional Paid in CapitalUSD | 17,272,661Source | — | 168,436,065Source | 17,068,433Source | — | 163,654,524Source | 2,954,764Source | — | 163,540,358Source | 2,954,764Source | 2,954,764Source |
| Retained Earnings (Accumulated Deficit)USD | -9,237,769Source | — | -65,626,043Source | -7,456,514Source | — | -45,452,913Source | -4,794,321Source | — | -10,393,061Source | -4,391,924Source | -3,001,934Source |
| Stockholders' Equity Attributable to ParentUSD | 8,160,652Source | -1,046,488Source | 106,448,541Source | 9,737,679Source | -713,967Source | 126,515,459Source | -1,760,518Source | -264,604Source | 153,347,827Source | -1,358,121Source | 31,869Source |
| Liabilities and EquityUSD | 9,250,036Source | — | 127,623,697Source | 10,546,681Source | — | 141,219,157Source | 259,904Source | — | 164,183,736Source | 13,057Source | 422,076Source |
| Current liabilities: | |||||||||||
| Liabilities, CurrentUSD | 1,089,384Source | — | 21,073,283Source | 809,002Source | — | 14,584,883Source | 1,770,422Source | — | 10,706,455Source | 1,024,334Source | 123,316Source |
| Operating Lease, Liability, CurrentUSD | — | — | 59,523Source | — | — | 52,339Source | — | — | 39,578Source | — | — |
| Operating Lease, Liability, NoncurrentUSD | — | — | 101,873Source | — | — | 118,815Source | — | — | 129,454Source | — | — |
| Additional Financial Items | |||||||||||
| Accrued Liabilities, CurrentUSD | — | — | 780,000Source | — | — | 575,000Source | — | — | 500,000Source | — | — |
| Short-term InvestmentsUSD | — | — | — | — | — | 1,500,000Source | — | — | 2,000,000Source | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | — | — | 1,565,806Source | — | 69,993Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -2,067,727Source | -20,313Source | -8,925,777Source | -733,526Source | -627,790Source |
| Cash flows from investing activities: | |||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | -15,345Source | — | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 490,606Source | — | -10,060,351Source | — | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 9,394Source | — | 57,333Source | — | — |
| Cash flows from financing activities: | |||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 920,000Source | 267,200Source | 20,619,327Source | 326,500Source | 1,032,100Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 6,986,617Source | 26,571Source | 8,278,371Source | 8,735,323Source | 8,979,534Source | 250,432Source | 9,636,655Source | 3,455Source | 410,481Source |
| Additional Financial Items | |||||||||||
| Accretion ExpenseUSD | — | — | — | — | — | — | 8,387Source | 11,256Source | 283,010Source | 79,953Source | 5,069Source |
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | 105,210Source | 192,053Source | — | 0Source | 2,044,186Source | 0Source | 69,993Source |
| DepreciationUSD | — | — | — | — | 4,662Source | 232Source | 20,044Source | — | 5,706Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | 458Source | — | -1,567Source | — | -521Source | — | — |
| General and Administrative ExpenseUSD | — | — | 1,224,546Source | 299,999Source | 5,319,018Source | 2,012,120Source | 11,284,550Source | 364,368Source | 10,279,981Source | 1,275,095Source | 648,892Source |
| InterestExpenseNonoperatingUSD | — | — | 6,301Source | 32,638Source | 3,223,755Source | 23,054Source | 859,405Source | 38,032Source | 283,011Source | 117,719Source | 38,069Source |
| Investment Income, InterestUSD | — | — | 56,426Source | 116Source | 21,764Source | 15,247Source | 7Source | 3Source | 107,595Source | 2,824Source | 7,811Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,781,255Source | -332,521Source | -20,173,129Source | -2,662,193Source | -35,059,852Source | -402,397Source | -6,001,137Source | -1,389,990Source | -777,694Source |
| Nonoperating Income (Expense)USD | — | — | 62,984Source | -32,522Source | -13,894,369Source | 1,711Source | -22,874,158Source | -38,029Source | 5,911,425Source | -114,895Source | -30,258Source |
| Operating ExpensesUSD | — | — | 1,844,239Source | 299,999Source | 6,278,760Source | 2,663,904Source | 12,185,694Source | 364,368Source | 11,912,562Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 11,629,727Source | — | 1,055,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | — | — | 1,822,115Source | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -1,844,239Source | -299,999Source | -6,278,760Source | -2,663,904Source | -12,185,694Source | -364,368Source | -11,912,562Source | -1,275,095Source | -747,436Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,781,255Source | -332,521Source | -20,173,129Source | -2,662,193Source | -35,059,852Source | -402,397Source | -6,001,137Source | -1,389,990Source | -777,694Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.14Source | -0.04Source | -11.77Source | -2.57Source | -2.26Source | -0.05Source | -0.55Source | -0.18Source | -0.17Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.14Source | -0.04Source | -11.77Source | -2.57Source | -2.26Source | -0.05Source | -0.55Source | -0.18Source | -0.17Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 12,575,983Source | 7,903,850Source | 1,713,402Source | 1,036,913Source | 15,513,389Source | 7,903,850Source | 10,881,907Source | 7,903,850Source | 4,598,265Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 12,575,983Source | 7,903,850Source | 1,713,402Source | 1,036,913Source | 15,513,389Source | 7,903,850Source | 10,881,907Source | — | — |
| Interest Expense (non-operating)USD | — | — | 6,301Source | 32,638Source | 3,223,755Source | 23,054Source | 859,405Source | 38,032Source | 283,011Source | 117,719Source | 38,069Source |
| Additional Financial Items | |||||||||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | 458Source | — | -1,567Source | — | -521Source | — | — |
| General and Administrative ExpenseUSD | — | — | 1,224,546Source | 299,999Source | 5,319,018Source | 2,012,120Source | 11,284,550Source | 364,368Source | 10,279,981Source | 1,275,095Source | 648,892Source |
| Investment Income, InterestUSD | — | — | 56,426Source | 116Source | 21,764Source | 15,247Source | 7Source | 3Source | 107,595Source | 2,824Source | 7,811Source |
| Nonoperating Income (Expense)USD | — | — | 62,984Source | -32,522Source | -13,894,369Source | 1,711Source | -22,874,158Source | -38,029Source | 5,911,425Source | -114,895Source | -30,258Source |
| Operating ExpensesUSD | — | — | 1,844,239Source | 299,999Source | 6,278,760Source | 2,663,904Source | 12,185,694Source | 364,368Source | 11,912,562Source | — | — |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | — | — | 1,822,115Source | — | — |
| Research and Development ExpenseUSD | — | — | 619,693Source | — | 959,742Source | 651,784Source | 901,144Source | — | 1,632,581Source | — | 98,544Source |
| Interest Expense, Debt | — | — | — | — | — | —Source | —Source | —Source | — | — | — |
| Other Income | — | — | — | — | — | —Source | — | — | — | — | — |
Offerings
Registration 333-282324
- Gross proceeds
- 13500000.0
- Net proceeds
- 12555000.0
- Deal price
- 4.0
- Shares
- 3375000
- Offering price
- $4.00
- Ticker
- APUS
Filing attachments
ea030825001ex99-1.htm · 8-K · 2026-10-13
Exhibit 99.1 MindWave Innovations Signs Agreement with US-Based BlockAssure to Build and Operate AssureChain, an End-to-End Insurance and Reinsurance Network AssureChain, a dedicated subnet of MindChain, will run every insurance function on-chain, while MindChain provides settlement and anchoring to Ethereum MATAWAN, New Jersey, Oct. 4, 2026 - via IBN - MindWave Innovations Inc. USA (“MindWave”), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. ( NYSE American: APUS ), has signed…
Read attachment ↗ea030692401ex99-1.htm · 8-K · 2026-09-29
Exhibit 99.1 MindWave Innovations Inc to Power AQUAEChain with Its MindChain Blockchain Infrastructure Agreement strengthens MindWave’s position as a technology provider for ecosystem finance and environmental markets MATAWAN, New Jersey - September 24, 2026 - MindWave Innovations Inc. (“MindWave”), a subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS), has entered into a 12-month strategic technology services agreement with Singapore-based AQUAE Holdings Pte. Ltd. (“AQUAE”) …
Read attachment ↗ea030692401ex99-2.htm · 8-K · 2026-09-29
Exhibit 99.2 MindWave Innovations Expands U.S. Commercial Footprint with Second Agreement to Build and Operate FlashChain for New York-Based Flash Sports & Media The 12-month agreement covers a dedicated MindChain subnet for authenticating digital match tickets, sports memorabilia and media assets MATAWAN, New Jersey, Sept. 29, 2026 - MindWave Innovations Inc. (“MindWave”), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS), has signed a 12-month software deve…
Read attachment ↗ea029198201ex4-1.htm · 10-Q · 2026-05-26
Exhibit 4.1 Personal and Confidential December 1, 2025 Apimeds Pharmaceuticals US, Inc. Dr. Vin Menon Chief Executive Officer 100 Matawan Rd, Suite 325 Matawan, New Jersey Re: Financial Advisory Agreement (this “Agreement”) Dear Mr. Menon, E.F. Hutton & Co. LLC (“E.F. Hutton & Co. ”) is pleased to act as an exclusive financial advisor for Apimeds Pharmaceuticals US, Inc., (separately or together with its subsidiaries and affiliates referred to herein as the “Company”, and together with…
Read attachment ↗ea028834401ex4-1.htm · 10-K · 2026-05-04
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary of the capital stock of Apimeds Pharmaceuticals US, Inc. (the “Company”), does not purport to be complete and is qualified in its entirety by reference to our Amended and Restated Certificate of Incorporation, as amended (the “Charter”), and our amended and restated bylaws (the “Bylaws”), each of which are incorporated by reference as an exhibi…
Read attachment ↗ea028720301ex99-1_apimeds.htm · 8-K · 2026-04-22
EX-99.1 2 ea028720301ex99-1_apimeds.htm PRESS RELEASE DATED APRIL 21, 2026 Exhibit 99.1 Apimeds Pharmaceuticals Receives Notice from NYSE Regulation Regarding Late Filing of Annual Report Matawan, N.J. April 22, 2026 -- (NYSE American: APUS) Apimeds Pharmaceuticals US, Inc. (the “Company”), today announced that on April 17, 2026, it received a notice of non-compliance (the “Notice”) with the continued listing standards set forth in Section 1007 of the Company Guide of NYSE American LLC (“N…
Read attachment ↗